Tamoxifen
تاموکسیفن
🎗️ Antineoplastic And Immunomodulating AgentsSelective estrogen receptor modulator (SERM)
Market / country: 🇺🇸 USA
Nolvadex (US)
🧮 Dose calculator
Breast cancer (hormonal therapy) · Regimen source: FDA Tamoxifen · Dosage and Administration
- • Only under an oncologist; dose is adjusted by response and toxicity. FDA Tamoxifen · Dosage and Administration
- • Doses above 20 mg/day split morning and evening. Adjuvant therapy usually 5 years. FDA Tamoxifen · Dosage and Administration
Enter age (weight is optional for this regimen).
🛡️ Safety & information
Contraindications
- ⛔ Hypersensitivity to tamoxifen. DCIS and risk reduction: need for coumarin anticoagulants or history of DVT or pulmonary embolism. FDA Tamoxifen · Contraindications
Warnings
- • Boxed warning (DCIS and risk reduction): uterine malignancies, stroke and pulmonary embolism — sometimes fatal. FDA Tamoxifen · Boxed Warning
Important interactions
- • Warfarin: marked increase in anticoagulant effect. FDA Tamoxifen · Contraindications
Formulations
- 10 mg tablet — tablet 🇺🇸 USA FDA Tamoxifen · How Supplied
- 20 mg tablet — tablet 🇺🇸 USA FDA Tamoxifen · How Supplied
👥 Special populations
- 🤰 PregnancyDangerous / avoid
Label: can cause fetal harm. Dangerous in pregnancy. FDA Tamoxifen · Pregnancy
“Pregnancy Category D Tamoxifen may cause fetal harm when administered to a pregnant woman.”
- 🤱 BreastfeedingDangerous / avoid
Label: breastfeeding not recommended, or choose between the drug and breastfeeding. FDA Tamoxifen · Nursing Mothers
“Because of the potential for serious adverse reactions in nursing infants from tamoxifen, women taking tamoxifen should not breast-feed.”
- 👶 ChildrenUse with caution
The label has conditions, age limits or notes for children; the label sentence is quoted below. FDA Tamoxifen · Pediatric Use
“The safety and efficacy of tamoxifen for girls aged 2 to 10 years with McCune-Albright Syndrome and precocious puberty have not been studied beyond one year of treatment.”
- 👴 Older adultsUse with caution
Label: use with caution in older adults, usually starting at the low end of the dose range. FDA Tamoxifen · Geriatric Use
“A reduction in breast cancer incidence was seen among participants in each of the subsets: A total of 28 and ten invasive breast cancers were seen among participants 65 and older in the placebo and tamoxifen groups, respectively.”
- ⚥ Females & males of reproductive potentialNo data
The source for this drug has no section for this group.
🔗 Reference links
- FDA (approval record)ANDA074732
- DailyMed (FDA label)FDA Tamoxifen
- MedlinePlus (NIH)Tamoxifen
- WHO ATC/DDDL02BA01
- Darooyab (Iran)Tamoxifen
🇮🇷 Registered in Iran Darooyab · G-1070/Tamoxifen
Dosage forms with Iranian generic codes, per Darooyab.
- 01193 · TAMOXIFEN CITRATE 10MG TAB · قرص تاموکسیفن سیترات ۱۰ میلیگرم
- 02465 · TAMOXIFEN CITRATE 20MG TAB · قرص تاموکسیفن سیترات ۲۰ میلیگرم
📚 Reference status for this drug
Shows which sources have references recorded for this drug and which do not.
- FDA label (DailyMed)✅ PresentFDA Tamoxifen · How SuppliedFDA Tamoxifen · Dosage and AdministrationFDA Tamoxifen · ContraindicationsFDA Tamoxifen · Boxed WarningFDA Tamoxifen · SPL approval / marketing categoryFDA Tamoxifen · PregnancyFDA Tamoxifen · Nursing MothersFDA Tamoxifen · Pediatric UseFDA Tamoxifen · Geriatric Use
- UK SmPC (eMC / MHRA)❌ Not present
- Published guideline❌ Not present
- Licensed reference (medical school)❌ Not present
- Iranian leaflet (IFDA)❌ Not present
- Pharmacy website (secondary, unreliable)✅ PresentDarooyab · G-1070/Tamoxifen
- Clinical review⚠ Unverified